---
title: "Ananda Pharma says MRX1 CBD drug clears… | Cannabivo"
description: "Ananda Pharma has released MRX1 safety data as it prepares clinical pain trials for its CBD oral solution."
canonical: https://cannabivo.com/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near
language: en
robots: index, follow
og_type: article
type: research-article
language_alternates:
  en: https://cannabivo.com/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near.md
  cs: https://cannabivo.com/cs/novinky/veda/ananda-pharma-lek-mrx1-s-cbd-prekonal-bezpecnostni-prekazku-klinicke-studie-bolesti-se-blizi.md
  de: https://cannabivo.com/de/news/wissenschaft/ananda-pharma-mrx1-cbd-sicherheits-huerde-schmerzstudien-ruecken-naeher.md
  es: https://cannabivo.com/es/noticias/ciencia/ananda-pharma-dice-que-el-farmaco-mrx1-de-cbd-supera-un-obstaculo-de-seguridad-mientras-se-acercan-los-ensayos-de-dolor.md
  fr: https://cannabivo.com/fr/actualites/science/ananda-pharma-declare-que-le-medicament-mrx1-cbd-franchit-un-obstacle-de-securite-alors-que-les-essais-contre-la-douleur-approchent.md
  hu: https://cannabivo.com/hu/hirek/tudomany/az-ananda-pharma-szerint-az-mrx1-cbd-gyogyszer-teljesitette-a-biztonsagi-kuszbot-mikozben-kozelitenek-a-fajdalomvizsgalatok.md
  it: https://cannabivo.com/it/notizie/scienza/ananda-pharma-farmaco-cbd-mrx1-supera-ostacolo-sicurezza-studi-dolore-si-avvicinano.md
  nl: https://cannabivo.com/nl/nieuws/wetenschap/ananda-pharma-mrx1-cbd-medicijn-passeert-veiligheidsdrempel-pijnonderzoeken-naderen.md
  pl: https://cannabivo.com/pl/aktualnosci/nauka/ananda-pharma-mrx1-lek-z-cbd-pokonuje-przeszkode-bezpieczenstwa-badania-bolu-zblizaja-sie.md
  pt: https://cannabivo.com/pt/noticias/ciencia/ananda-pharma-mrx1-cbd-ultrapassa-barreira-seguranca-ensaios-dor.md
  ru: https://cannabivo.com/ru/novosti/nauka/ananda-pharma-zayavlyaet-chto-preparat-mrx1-s-cbd-proshel-proverku-bezopasnosti-pered-klinicheskimi-ispytaniyami-pri-boli.md
  tr: https://cannabivo.com/tr/haberler/bilim/ananda-pharma-mrx1-cbd-ilaci-guvenlik-engelini-asti-agri-denemelerine-yaklasiyor.md
  zh: https://cannabivo.com/zh/news/kexue/annada-zhiyao-cheng-mrx1-cbd-yaowu-tongguo-anquan-menkan-tengtong-shiyan-linjin.md
  ja: https://cannabivo.com/ja/news/kagaku/ananda-faama-mrx1-cbd-anzen-sei-hadoru-kuria-toutsuu-shiken.md
  ar: https://cannabivo.com/ar/akhbar/ilm/ananda-pharma-dawa-mrx1-cbd-yajtaz-hajiz-al-salama-ma-aqtarab-tajareb-al-alam.md
  ko: https://cannabivo.com/ko/news/gwahak/ananda-pama-mrx1-cbd-yakmul-anjeonseong-heodeul-tonggwahamyeo-tongjeung-imsangsiheom-geunjub.md
  pt-br: https://cannabivo.com/pt-br/noticias/ciencia/ananda-pharma-diz-que-o-medicamento-mrx1-cbd-supera-obstaculo-de-seguranca-testes-dor-se-aproximam.md
  hi: https://cannabivo.com/hi/samachar/vigyan/ananda-pharma-ka-kahna-mrx1-cbd-dawa-ne-suraksha-badha-par-ki-dard-parikshan-nazdeek.md
generated: 2026-07-29
---

> **Machine-readable Markdown rendering.** This is a Markdown representation of a web page,
> served for AI agents and crawlers as a token-efficient alternative to the full HTML.
> Full interactive HTML version: https://cannabivo.com/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near
> Canonical URL: https://cannabivo.com/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near
> Available languages: en, cs, de, es, fr, hu, it, nl, pl, pt, ru, tr, zh, ja, ar, ko, pt-br, hi

[![Clinical trial documents and a CBD medicine bottle on a laboratory counter](/images/uploads/aac392f6-437e-4202-96b5-63944118d26f/news-hero-ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near-1920x1080.jpg)](/images/uploads/aac392f6-437e-4202-96b5-63944118d26f/news-hero-ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near-1920x1080.avif "View image full size")

[Science](/news/science "Science")

7 min read

# Ananda Pharma says MRX1 CBD drug clears safety hurdle as pain trials near

![Portrait of Rob Harley, Cannabivo news desk](/images/uploads/5f094d99-3443-4907-8555-2910851fd38a/rob-harley-1920x1920.jpg)By [Rob Harley](/user-profile?u=a65dddce-73db-40b5-8660-fe93612a7384 "View the author's member profile")Published June 17, 2026in [Science](/news/science "Science")

 Ananda Pharma has released MRX1 safety data as it prepares clinical pain trials for its CBD oral solution.

![Portrait of Rob Harley, Cannabivo news desk](/images/uploads/5f094d99-3443-4907-8555-2910851fd38a/rob-harley-1920x1920.jpg)By [Rob Harley](/user-profile?u=a65dddce-73db-40b5-8660-fe93612a7384 "View the author's member profile")

Rob Harley has reported on cannabis law and the non-profit association movement across Europe for the past decade. He focuses on how regulation actually reaches the members who use cannabis social clubs — the paperwork, the limits, and the slow build of public trust. His work for Cannabivo aims to be accurate, sourced, and free of hype.

[More articles by this author](/news/author/rob-harley "See all articles by this author")Published June 17, 2026in [Science](/news/science "Science")

 In this article1. [MRX1’s safety data sets up the next stage](/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near#mrx1-s-safety-data-sets-up-the-next-stage "MRX1’s safety data sets up the next stage")
2. [What Ananda has disclosed so far](/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near#what-ananda-has-disclosed-so-far "What Ananda has disclosed so far")
3. [Safety is the hinge between CBD formulations and pain studies](/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near#safety-is-the-hinge-between-cbd-formulations-and-pain-studies "Safety is the hinge between CBD formulations and pain studies")
4. [Ananda’s update lands in a broader cannabis-drug market](/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near#ananda-s-update-lands-in-a-broader-cannabis-drug-market "Ananda’s update lands in a broader cannabis-drug market")
5. [What the next pain trial will be asked to prove](/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near#what-the-next-pain-trial-will-be-asked-to-prove "What the next pain trial will be asked to prove")
6. [A measured step, not a finished verdict](/news/science/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near#a-measured-step-not-a-finished-verdict "A measured step, not a finished verdict")

Ananda Pharma has moved its **MRX1 CBD oral solution** another step closer to clinical pain trials after publishing the full clinical study report from its phase 1 work. The company says the study supports the drug’s safety profile, adding fresh momentum to a program that is now shifting from early tolerability work toward a more direct test in pain patients.

## MRX1’s safety data sets up the next stage

Ananda Pharma’s latest disclosure is not a commercial launch milestone, but it is an important one for a development program that depends on credibility in the clinic. According to [Business of Cannabis](https://businessofcannabis.com/ananda-pharma-confirms-safety-of-mrx1-cbd-drug-as-clinical-pain-trials-approach/ "Business of Cannabis"), the company has now published the full clinical study report from its phase 1 work on MRX1, a CBD oral solution, and says the findings confirm the product’s safety as pain trials approach.

That matters because early-stage cannabinoid medicines live or die on the quality of their safety package. A phase 1 study does not answer whether a treatment works for pain, but it is the gatekeeper for what can be tested next. In this case, Ananda’s report is aimed at supporting that transition, not replacing it.

Why this update matters

Phase 1 safety data does not prove efficacy, but it can determine whether a candidate drug is ready to move into the more demanding pain-trial stage.

[![Clinical research documents and trial notes on a desk in a laboratory office setting.](/images/uploads/a5e5f8a3-22e5-4ae8-8ec0-855d11d643ca/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near-clinical-researc-1920x1080.jpg)](/images/uploads/a5e5f8a3-22e5-4ae8-8ec0-855d11d643ca/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near-clinical-researc-1920x1080.avif "View image full size")

Ananda’s MRX1 update centres on the release of the full clinical study report from phase 1 work.

## What Ananda has disclosed so far

The public record in the supplied facts is focused on the phase 1 pharmacokinetic study and the company’s conclusion that safety and tolerability remain on track. A separate [Investing.com report on dosing completion](https://www.investing.com/news/company-news/ananda-pharma-completes-dosing-in-phase-1-trial-of-cbd-formulation-93CH-4284205 "Investing.com report on dosing completion") says the Melbourne study was designed to evaluate pharmacokinetics, safety and tolerability, and that dosing has been completed.

That earlier milestone is consistent with the newer disclosure. Another company update, also carried by [Investing.com](https://www.investing.com/news/company-news/ananda-completes-dosing-phase-in-mrx1-cbd-phase-1-trial-93CH-4271557 "Investing.com"), described the last-participant, last-dose milestone in the MRX1 phase 1 pharmacokinetic study and said safety and tolerability results were expected later in the year. The latest announcement appears to be that follow-through.

MRX1 at a glance

phase 1stage already completed

Melbournetrial location

last-participant, last-dosedosing milestone reached

later in the yearexpected timing for results in the earlier update

What the supplied facts say about MRX1’s development track
| Milestone | What the facts say | Source |
|---|---|---|
| Phase 1 study | Designed to assess pharmacokinetics, safety and tolerability | [Investing.com dosing report](https://www.investing.com/news/company-news/ananda-pharma-completes-dosing-in-phase-1-trial-of-cbd-formulation-93CH-4284205 "Investing.com dosing report") |
| Dosing completion | The company said it reached the last-participant, last-dose milestone | [Investing.com MRX1 update](https://www.investing.com/news/company-news/ananda-completes-dosing-phase-in-mrx1-cbd-phase-1-trial-93CH-4271557 "Investing.com MRX1 update") |
| Latest disclosure | Ananda published the full clinical study report and confirmed safety | [Business of Cannabis](https://businessofcannabis.com/ananda-pharma-confirms-safety-of-mrx1-cbd-drug-as-clinical-pain-trials-approach/ "Business of Cannabis") |

## Safety is the hinge between CBD formulations and pain studies

For a CBD-based medicine, safety is not a side issue. It is the hinge on which the rest of development turns. The MRX1 program is moving from an early pharmacokinetic study into the phase where pain-specific questions can be asked, and that sequence only works if the initial profile is clean enough to justify the next step.

The supplied facts do not identify the pain indication, the dose strategy, or any efficacy claims, and that restraint is part of the story. At this stage, Ananda is talking about readiness. The next trial is where the company will begin to find out whether that readiness translates into a meaningful clinical case.

[![A clinical researcher reviewing safety charts and trial paperwork in an office.](/images/uploads/77751add-9d81-4949-8eae-46ae6a2db417/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near-researcher-revie-1920x1080.jpg)](/images/uploads/77751add-9d81-4949-8eae-46ae6a2db417/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near-researcher-revie-1920x1080.avif "View image full size")

The next stage for MRX1 depends on whether the safety record can support a pain-trial programme.- Phase 1 establishes basic pharmacokinetics and tolerability before later-stage testing.
- Safety disclosure is the bridge from formulation work to disease-specific trials.
- MRX1’s latest update is about readiness, not a claim of proven pain relief.

## Ananda’s update lands in a broader cannabis-drug market

The MRX1 announcement also arrives as the wider cannabis-medical sector continues to look for clearer regulatory and commercial footing. That context matters, even if it is not the core of the Ananda story. Europe’s cannabis policy picture remains unsettled, and in Germany, policy debates over medical access and reimbursement continue to shape the market environment.

For example, the German Hemp Association has argued in a [statement on the government’s health-insurance savings draft](https://hanfverband.de/dhv-stellungnahme-zum-regierungsentwurf-gkv-beitragssatzstabilisierungsgesetz "statement on the government’s health-insurance savings draft") that cannabis flowers remain necessary in medical care and that the proposed changes could create more costs than savings. Separately, the same association’s [live reporting from Mary Jane Berlin](https://hanfverband.de/live-von-der-mary-jane-berlin-dhv-news-511 "live reporting from Mary Jane Berlin") noted that discussions around health-insurance coverage for flower had reached the Bundestag. Those debates sit outside Ananda’s trial programme, but they show why medical-cannabis evidence remains commercially sensitive.

Even so, MRX1’s immediate story is narrower and more concrete than those policy fights. A drug candidate does not get to a pain trial because the market is favourable; it gets there because the early data are sufficient. That is the terrain Ananda is now trying to cross.

## What the next pain trial will be asked to prove

The facts supplied here do not spell out the design of the upcoming pain studies, but they do make the development path clear. Once safety and tolerability have been confirmed at phase 1 level, the scientific question shifts from “can this be given?” to “does it do anything useful in the intended condition?”

That transition is where many cannabinoid candidates stall. Early-stage tolerability can open the door, but pain trials are where regulators, clinicians and investors start looking for practical evidence rather than promise. Ananda’s latest report therefore functions as a checkpoint: it keeps the program alive and gives the company permission to ask the harder question next.

How the MRX1 development sequence is presented in the supplied facts
| Stage | Focus | Status in the facts |
|---|---|---|
| Phase 1 pharmacokinetic study | Safety, tolerability and how the drug behaves in the body | Completed dosing; safety report published |
| Next pain trials | Clinical testing in pain | Approaching |
| Commercial outcome | Market entry | Not addressed in the supplied facts |

## A measured step, not a finished verdict

There is a disciplined quality to the way this update reads. Ananda has not presented MRX1 as a breakthrough cure, and the facts supplied here do not support that kind of language anyway. What they do support is a straightforward development milestone: phase 1 work is complete, the company says the safety profile holds up, and the programme is moving toward pain trials.

That is enough to matter. In drug development, especially in cannabinoid medicine, safety confirmations can be the difference between a programme that progresses and one that stops at the threshold. MRX1 is now closer to the second question, which is the one patients and physicians ultimately care about.

[![A medicine bottle and clinical trial folder on a laboratory counter.](/images/uploads/c072088b-aa54-47fc-aefb-bd43d97e2bac/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near-pharmacy-style-m-1920x1080.jpg)](/images/uploads/c072088b-aa54-47fc-aefb-bd43d97e2bac/ananda-pharma-says-mrx1-cbd-drug-clears-safety-hurdle-as-pain-trials-near-pharmacy-style-m-1920x1080.avif "View image full size")

MRX1’s next step is clinical, not commercial: the drug now moves toward pain testing.Key takeaways

- Ananda Pharma says its \*\*MRX1 CBD oral solution\*\* has cleared a safety hurdle after phase 1 work.
- The company published the full clinical study report as it prepares for \*\*pain trials\*\*.
- Earlier updates said the Melbourne study examined pharmacokinetics, safety and tolerability, and dosing was completed.
- The latest news is about readiness for the next clinical stage, not proof of pain relief.
- For cannabinoid medicines, confirmed safety is the key step that allows efficacy testing to begin.

Ananda Pharma’s latest MRX1 update is a procedural milestone with real weight behind it. By confirming safety and releasing the full phase 1 study report, the company has strengthened the case for moving its CBD oral solution into pain trials. The evidence now points to a programme that is progressing on schedule, but the central question still lies ahead: whether MRX1 can do more than clear the safety bar and actually deliver clinically useful results.

## Sources

1. [Ananda Pharma Confirms Safety of MRX1 CBD Drug, as Clinical Pain Trials Approach (businessofcannabis.com)](https://businessofcannabis.com/ananda-pharma-confirms-safety-of-mrx1-cbd-drug-as-clinical-pain-trials-approach/ "Open source in a new tab: https://businessofcannabis.com/ananda-pharma-confirms-safety-of-mrx1-cbd-drug-as-clinical-pain-trials-approach/")
2. [Ananda Pharma completes dosing in phase 1 trial of CBD formulation (investing.com)](https://www.investing.com/news/company-news/ananda-pharma-completes-dosing-in-phase-1-trial-of-cbd-formulation-93CH-4284205 "Open source in a new tab: https://www.investing.com/news/company-news/ananda-pharma-completes-dosing-in-phase-1-trial-of-cbd-formulation-93CH-4284205")
3. [Ananda completes dosing phase in MRX1 CBD phase 1 trial (investing.com)](https://www.investing.com/news/company-news/ananda-completes-dosing-phase-in-mrx1-cbd-phase-1-trial-93CH-4271557 "Open source in a new tab: https://www.investing.com/news/company-news/ananda-completes-dosing-phase-in-mrx1-cbd-phase-1-trial-93CH-4271557")
4. [DHV-Stellungnahme zum Regierungsentwurf „GKV-Beitragssatzstabilisierungsgesetz“ (hanfverband.de)](https://hanfverband.de/dhv-stellungnahme-zum-regierungsentwurf-gkv-beitragssatzstabilisierungsgesetz "Open source in a new tab: https://hanfverband.de/dhv-stellungnahme-zum-regierungsentwurf-gkv-beitragssatzstabilisierungsgesetz")
5. [Live von der Mary Jane Berlin | DHV-News

# 511 (hanfverband.de)](https://hanfverband.de/live-von-der-mary-jane-berlin-dhv-news-511 "Open source in a new tab: https://hanfverband.de/live-von-der-mary-jane-berlin-dhv-news-511")